02651nas a2200265 4500008004100000245018300041210006900224260001800293300001200311490000700323520174900330653002702079653001602106653003102122653001502153653001102168100002402179700002802203700002102231700002302252700002802275700002502303700002102328856003602349 2023 eng d00aSafety Assessment of Supplementation with Cymbopogon citratus Stapf. (Lemongrass) Extract in Patients with Chronic Kidney Disease Stage 3: A Preliminary 90-Days Prospective Study0 aSafety Assessment of Supplementation with Cymbopogon citratus St cDecember 2023 a976-9860 v153 a

Background: Chronic kidney disease is a major public health issue, and due to resource constraints, many can't access dialysis. C. citratus, lemongrass is globally prevalent and known to increase urine output without toxicity. Objective: To examine the safety of C. citratus in patients with CKD stage 3. Materials and Methods: The major compound of C. citratus was analyzed using high-performance liquid chromatography (HPLC). 64 patients were enrolled and randomly assigned to control or C. citratus groups. The control group received a placebo, whereas the C. citratus group received 900 mg of C. citratus daily for 90 days. All participants were examined BUN, Scr, Cys-C, and eGFR, liver functions, RBC, HCT, Na+, K+, Cl-, and HCO3, and other biochemical parameters. Results: HPLC showed C. citratus contains of phenolic compounds. Clinically, C. citratus group had no notable side effects on T-Bil, AST, ALT and ALP. Also, maintained eGFR, SCys-C, K+ and Cl level. The level of blood Na+ was significant increase at day 30 (p < 0.05). The control group had a significant decrease in eGFR and HCO3 levels (p < 0.05) and a significant increase of Cl- and SCys-C. In addition, no statistical differences had found between groups in eGFR, BUN, Cr, Na+, K+, HCO3, PO4, RBC and HCT levels. Throughout the 90 days, no drug allergies or side effects were reported. Conclusion: Dietary supplementation with C. citratus may have a favorable effect on delaying the course of CKD and is safe to use for patients with CKD stage 3.

10aChronic Kidney Disease10aCKD stage 310aCymbopogon citratus Stapf.10aLemongrass10aSafety1 aWongmanit, Patnaree1 aTungsukruthai, Parunkul1 aPhetkate, Pratya1 aRungprai, Daraporn1 aTungsukruthai, Sucharat1 aSupasyndh, Ouppatham1 aSriyakul, Kusuma uhttps://phcogj.com/article/2149